Evidence map›Paper›PMID 27837716›Full record

ArticleJournal of colloid and interface science2017

Probing mucin interaction behavior of magnetic nanoparticles.

Vijayakumar N Boya, Renn Lovett, Saini Setua, Vaibhav Gandhi, Prashanth K B Nagesh, Sheema Khan, Meena Jaggi, Murali M Yallapu, Subhash C Chauhan

Abstract read
In one paragraph

Article in Journal of colloid and interface science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Nanoencapsulation of vitamin BJournal of food science · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vijayakumar N BoyaDepartment of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38105, USA; Department of Materials Science and Nanotechnology, Yogi Vemana University, Kadapa 516 001, AP, India.
Renn LovettDepartment of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38105, USA.
Saini SetuaDepartment of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38105, USA.
Vaibhav GandhiDepartment of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38105, USA.
Prashanth K B NageshDepartment of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38105, USA.
Sheema KhanDepartment of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38105, USA.
Meena JaggiDepartment of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38105, USA.
Murali M YallapuDepartment of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38105, USA. Electronic address: myallapu@uthsc.edu.
Subhash C ChauhanDepartment of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38105, USA. Electronic address: schauhan1@uthsc.edu.

Funding

Development of Targeted Nanotechnology Platform for Pancreatic CancerR01CA206069 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7M
Targeted Nanotherapy for Pancreatic CancerR01CA210192 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7M
Etiology of cervical cancer health disparity in American Indian womenU01CA162106 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI CHAUHAN, SUBHASH C., JAGGI, MEENA · 2012 to 2016
$1.5M
PSMA Targeted Docetaxel Loaded Magnetic Nanoparticles for Prostate Cancer TherapyK22CA174841 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI YALLAPU, MURALI MOHAN · 2015 to 2017
$485k
NCI NIH HHS K22 CA174841NCI NIH HHS R01 CA206069NCI NIH HHS R01 CA210192NCI NIH HHS U01 CA162106
6 · The paper itself

Abstract

In this study, we developed iron oxide based magnetic nanoparticles (MNPs) by precipitation of iron salts in the presence of ammonia and created four different formulations: without functionality (plain MNPs, no coating), with β-cyclodextrin (MNPs+β-CD) or pluronic 127 polymer (MNPs+F-127), and both β-cyclodextrin and pluronic 127 polymer (MNPs+β-CD-F-127) functionality for its efficient use in mucosal delivery. We studied the interaction and/or binding behavior of these MNPs formulations with porcine stomach mucin using steady-state fluorescence spectroscopy, and then quantified the bound mucin from absorption studies. Toxicity of these MNPs against cervical cancer cells and red blood cells was evaluated. Ex-vivo studies were performed using freshly collected gastrointestinal, ovarian, pancreas and colon organ tissues of pig to evaluate binding and uptake phenomenon of MNPs. Transport studies of these MNPs in mucin was evaluated using Boyden's chamber assay. All these studies together suggest that the MNPs+β-CD-F-127 formulation was strongly interacted with mucin and interestingly transported through mucin compared to other MNPs formulations. Hence, MNPs+β-CD-F-127 formulation could be a good candidate for the mucoadhesive biopharmaceuticals and drug delivery system.

Indexed as

AmmoniaAnimalsbeta-CyclodextrinsBiological TransportCell Line, TumorCell SurvivalColonDrug CarriersFemaleFerric CompoundsGastric MucosaHumansMagnetite NanoparticlesMucinsOvaryPancreasAmmoniabeta-CyclodextrinsbetadexDrug CarriersFerric Compoundsferric oxideMagnetite NanoparticlesMucinsPoloxamerCancerDrug deliveryMagnetic nanoparticlesMucinMucoadhesive pharmaceuticals

Identifiers

PMID27837716
PMCPMC5461659

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.